Skip to main
ASRT

ASRT Stock Forecast & Price Target

ASRT Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Assertio Hldgs is poised for success due to the increased offer and fully-committed financing commitments from Garda Therapeutics, representing a premium to the original offer and a significant increase from Assertio's pre-offer stock price. The company's Board of Directors has determined that this offer provides the most favorable outcome for stockholders, leading to a Buy rating and a raised price target of $21.80 per share. The successful completion of the transaction is expected to further boost the company's financials and remove its common stock from public trading.

Bears say

Assertio Hldgs is projected to face significant challenges in the near future due to a sharp decrease in service revenue and other income, as well as a significant loss on impairment of intangible assets. These factors will likely lead to a decrease in profitability and threaten the company's ability to meet its financial obligations and fund future growth initiatives. The recent reverse stock split may provide temporary relief, but given the heightened risks and uncertainties faced by the company, we maintain our negative outlook on its stock.

ASRT has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assertio Therapeutics Inc (ASRT) Forecast

Analysts have given ASRT a Hold based on their latest research and market trends.

According to 2 analysts, ASRT has a Hold consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assertio Therapeutics Inc (ASRT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.